Medical News

[ Selective Estrogen Receptor Modulators For Postmenopausal Osteoporosis - Clinical Guide ]

Selective Estrogen Receptor Modulators For Postmenopausal Osteoporosis - Clinical Guide

Elsevier, a world-leading provider of scientific, technical and medical information products and services, has announced the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas. This clinical guide details the role of selective estrogen receptor modulators (SERMs) against postmenopausal osteoporosis as the European Medicines Agency (EMA) has approved the use of bazedoxifene and lasofoxifene. Postmenopausal osteoporosis and resulting fractures have a major impact on morbidity and mortality and are major public health issues. Various therapies such as bisphosphonates, strontium ranelate and more recently denomsumab are available but these are not suitable for all women. Health concerns have been raised resulting from these therapies, such as oesophageal cancer, osteonecrosis of the jaw (ONJ) and subtrochanteric fractures with bisphosphonates and venous thromboembolism with strontiumranelate.

What Is Hyperthyroidism? What Causes Hyperthyroidism?

ThyroidGland Hyperthyroidism, also known as overactive thyroid, is a medical condition caused by an abnormally high level of thyroid hormone in the bloodstream. The thyroid gland produces an excessive amount of thyroid hormones. The thyroid gland is located in the neck. It produces hormones that are released into the bloodstream to control the body's growth and metabolism. Symptoms of hyperthyroidism may include a rapid heartbeat, hyperactivity, muscle weakness, sudden weight loss or gain, increased appetite and sensitivity to heat. The condition is more common in women than men. According to Medilexicon's medical dictionary, hyperthyroidism is: "An abnormality of the thyroid gland in which secretion of thyroid hormone is usually increased and no longer under regulatory control of hypothalamic-pituitary centers;

Breast Cancer May Regress When Hormone Therapy Ceases

As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, & Prevention. As part of the national Breast Cancer Surveillance Consortium, researchers studied 741, 681 woman-years of data (with a median of 3.3 years per woman) on 163, 490 women aged 50-79 who were Group Health Cooperative members and had no prior history of breast cancer. "This is the first study to look over time at screening mammography use among individual women by their hormone therapy status linked with their breast cancer diagnoses, " said lead author Diana S.M. Buist, PhD, a senior investigator at Group Health Research Institute. Previous research has shown a rapid decline in new breast cancers - and also in use of hormone therapy and of screening mammography - since 2002, when the Women's Health Initiative published that breast cancer rates were higher in women taking estrogen and progestin than in those taking either a placebo or only estrogen.

Quitting Hormone Therapy May Lead To Tumor Regression In Breast Cancer

A new study suggests that quitting hormone therapy (HT) has an immediate effect on breast cancer rates, supporting the idea that stopping it leads to tumor regression. The researchers refute the suggestion that former HT users are less inclined to undergo mammography screening and that this explains the reductions in breast cancer diagnosis, because they found, if anything, former HT users are more likely to undergo the screening. Lead author Dr Diana S.M. Buist, a senior investigator at Group Health Research Institute in Seattle, Washington, and colleagues, write about their findings in the journal Cancer Epidemiology, Biomarkers, & Prevention. Buist said in a statement released on Tuesday: "This is the first study to look over time at screening mammography use among individual women by their hormone therapy status linked with their breast cancer diagnoses.

Tackling Diabetes Care Challenges - Expert Groups Collaborate

The Endocrine Society, the American Pharmacists Association (APhA) and Opus Science, announce the launch of their new program in an effort to assess and improve care for those suffering from diabetes. The program called "Improving Quality in Type 2 Diabetes: A National Initiative to Assess Guideline Adherence and Physician/Pharmacist Coordination, " is part of a new U.S. multiphase initiative that is setting out to assess the effects of current in-practice behavior in multiple primary care and endocrinology clinics, as well as pharmacies, to provide care for patients suffering from type 2 diabetes. The initiative will also examine potential avenues to improve diabetes management by improving care coordination with local pharmacies and/or pharmacists. Janet E. Hall, MD, President of the Endocrine Society declared: "We are excited about this unique collaboration between The Endocrine Society and APhA.

Medical News © Nanda
Designer Damodar